Overview

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2033-04-15

Target enrollment:

Participant gender:

Summary

This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Building upon anti-HER2 targeted therapy combined with endocrine therapy, the addition of CDK4/6 inhibitors has demonstrated greater clinical benefits for advanced TPBC patients. This study aims to investigate the efficacy and safety of CDK4/6 inhibitor combination with standard adjuvant endocrine therapy in HR+/HER2+ early breast cancer patients.

Phase:

PHASE3

Details

Lead Sponsor:

Fudan University

Treatments:

Anastrozole
exemestane
Letrozole
Tamoxifen